SXTP Stock Overview
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
60 Degrees Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$8.65 |
| 52 Week Low | US$0.22 |
| Beta | 0 |
| 1 Month Change | -8.81% |
| 3 Month Change | -22.55% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| SXTP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.3% | 0.3% | 2.2% |
| 1Y | n/a | 9.8% | 22.8% |
Return vs Industry: Insufficient data to determine how SXTP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SXTP performed against the US Market.
Price Volatility
| SXTP volatility | |
|---|---|
| SXTP Average Weekly Movement | 15.0% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SXTP's share price has been volatile over the past 3 months.
Volatility Over Time: SXTP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3 | Geoffrey Dow | www.60degreespharma.com |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
60 Degrees Pharmaceuticals, Inc. Fundamentals Summary
| SXTP fundamental statistics | |
|---|---|
| Market cap | US$2.75m |
| Earnings (TTM) | -US$3.77m |
| Revenue (TTM) | US$253.57k |
10.9x
P/S Ratio-0.7x
P/E RatioIs SXTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SXTP income statement (TTM) | |
|---|---|
| Revenue | US$253.57k |
| Cost of Revenue | US$1.17m |
| Gross Profit | -US$912.75k |
| Other Expenses | US$2.85m |
| Earnings | -US$3.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -359.95% |
| Net Profit Margin | -1,485.06% |
| Debt/Equity Ratio | 3.3% |
How did SXTP perform over the long term?
See historical performance and comparison